Screening for SARS-CoV-2 non-structural protein 14 inhibitor

Screening for SARS-CoV-2 non-structural protein 14 inhibitors


Screening for SARS-CoV-2 non-structural protein 14 inhibitors
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome generates 16 distinct non-structural proteins (nsp) that constitute the enzymes and accessory proteins responsible for virus replication once inside a host cell. These protein complexes produce and cap RNA strands that will go on to be translated by the host machinery. Capping the RNA in a manner that is recognized as similar to endogenous mRNA ensures compatibility, lessens RNA degradation rates and lowers the probability of triggering an immune response in the host cell.
In a paper recently uploaded to the preprint server
et al. (April 8
th, 2021), inhibitors of one essential SARS-CoV-2 non-structural protein are explored, with four compounds, in particular, identified as potential antiviral leads that exhibit synergistic effects with antiviral drug remdesivir.

Related Keywords

Coomassie , Ashanti , Ghana , Diffleyet Al , Michael Greenwood , , Small Molecule Inhibitors , Image Credit , Protein , Sars , Sars Cov 2 , Structural Protein , Antiviral Drug , Cell , Corona Virus , Coronavirus Disease Covid 19 , Drugs , Enzyme , Genome , Guanine , Immune Response , Molecule , Remdesivir , Respiratory , Rna , Severe Acute Respiratory , Severe Acute Respiratory Syndrome , Syndrome , Virus , அசாந்தி , கானா , மைக்கேல் கிரீன்வுட் , படம் கடன் , ப்ரோடீந் , சர்ச் , கட்டமைப்பு ப்ரோடீந் , செல் , கொரோனா வைரஸ் , மருந்துகள் , நொதி , மரபணு , நோய் எதிர்ப்பு சக்தி பதில் , மூலக்கூறு , சுவாச , ர்ந , கடுமையானது எடுப்போசை சுவாச , கடுமையானது எடுப்போசை சுவாச நோய்க்குறி , நோய்க்குறி , வைரஸ் ,

© 2025 Vimarsana